Get the Stockscreener App
0.5486
0.25%
-0.0014
Pre-market:
.55
0.0014
+0.26%
Marinus Pharmaceuticals Inc stock is traded at $0.5486, with a volume of 1.13M.
It is down -0.25% in the last 24 hours and up +2.81% over the past month.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
See More
Previous Close:
$0.55
Open:
$0.5475
24h Volume:
1.13M
Relative Volume:
0.62
Market Cap:
$30.29M
Revenue:
$30.99M
Net Income/Loss:
$-141.41M
P/E Ratio:
-0.2086
EPS:
-2.63
Net Cash Flow:
$-118.12M
1W Performance:
+1.48%
1M Performance:
+2.81%
6M Performance:
-52.30%
1Y Performance:
-94.51%
1-Day Range:
$0.5461
$0.55
1-Week Range:
$0.54
$0.55
52-Week Range:
$0.2202
$10.50
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
Name
Marinus Pharmaceuticals Inc
Sector
Industry
Phone
484-801-4670
Address
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
Compare MRNS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNS
Marinus Pharmaceuticals Inc
|
0.5486 | 30.29M | 30.99M | -141.41M | -118.12M | -2.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-16-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-15-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-20-23 | Initiated | RBC Capital Mkts | Outperform |
| Sep-30-20 | Initiated | Truist | Buy |
| Jul-01-20 | Initiated | Cowen | Outperform |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-09-20 | Initiated | Craig Hallum | Buy |
| Dec-20-19 | Initiated | Oppenheimer | Outperform |
| Mar-05-19 | Resumed | Jefferies | Buy |
| Feb-27-19 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-19 | Initiated | Leerink Partners | Outperform |
| Jul-02-18 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-20-18 | Initiated | Mizuho | Buy |
| Feb-15-18 | Initiated | H.C. Wainwright | Buy |
| Dec-14-17 | Initiated | Laidlaw | Buy |
| Aug-10-16 | Reiterated | Jefferies | Buy |
| Jun-14-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-08-16 | Reiterated | Stifel | Buy |
| Dec-17-15 | Initiated | RBC Capital Mkts | Outperform |
| Nov-17-15 | Initiated | Jefferies | Buy |
| Oct-30-15 | Reiterated | Oppenheimer | Outperform |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
View All
Marinus Pharmaceuticals Inc Stock (MRNS) Latest News
MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Morgan Stanley's Strategic Acquisition of Marinus Pharmaceuticals Shares - GuruFocus.com
Vanguard Group Inc Reduces Holdings in Marinus Pharmaceuticals I - GuruFocus.com
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Marinus Pharmaceuticals director sells shares worth $869 - MSN
UPCOMING MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Marinus pharmaceuticals director sells shares for $864 - MSN
Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis - MarketBeat
Marinus pharmaceuticals director sells shares for $864 By Investing.com - Investing.com Canada
Immedica to buy Marinus Pharmaceuticals for $151m - MSN
Fragile X Syndrome Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Novartis, Neuren Pharma, Roche, Seaside Therapeutics, Inc., Marinus Pharma, Lysogene - Barchart
Fragile X Syndrome Market Predicted to See Upsurge Through 2034, - openPR
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of AE, MRNS, SASR, ROIC to Take Action - The Malaysian Reserve
Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints - MSN
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know - MSN
Beryl Capital Management LLC Acquires Significant Stake in Marin - GuruFocus.com
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Marinus Pharmaceuticals, Inc.MRNS - Kilgore News Herald
Immedica Pharma AB’s Acquisition of Marinus Pharmaceuticals - Global Legal Chronicle
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc.MRNS - Business Wire
Immedica acquires Marinus in $151 million deal - The Pharma Letter
Marinus Therapeutics in Radnor Acquired by Swedish Company - MSN
Immedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million Deal - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders - Marketscreener.com
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - Citeline News & Insights
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – VINC, VCSA, MRNS, MHLD - GlobeNewswire Inc.
Marinus executives in line for bonuses after acquisition deal triggers retention payouts - The Business Journals
After phase 3 setbacks, troubled Marinus inks $151M sale to Immedica Pharma - FiercePharma
$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the MergerVINC, VCSA, MRNS, MHLD - Stockhouse Publishing
Neutral rating reaffirmed for Marinus stock as acquisition deal closure nears - Investing.com Canada
Marinus Pharmaceuticals to be acquired by Immedica for 55c per share - Yahoo Finance
Immedica Pharma AB entered into definitive agreement to acquire Marinus Pharmaceuticals, Inc.. - Marketscreener.com
Orion and Marinus Terminate Agreement for ganaxolone in Europe - Marketscreener.com
Immedica to buy rare disease drugmaker Marinus for $151 million - Crain's Chicago Business
Immedica to acquire Marinus Pharmaceuticals for $151 million By Investing.com - Investing.com Canada
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Me - GuruFocus.com
Marinus Pharmaceuticals ends agreements with Orion Corporation By Investing.com - Investing.com Nigeria
Marinus Pharmaceuticals ends agreements with Orion Corporation - Investing.com India
Immedica Pharma AB entered into an agreement to acquire Marinus Pharmaceuticals, Inc.. - Marketscreener.com
Immedica to Acquire Marinus Pharmaceuticals in $151 Million Deal; Shares Surge 43% - GuruFocus.com
Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40% - Benzinga
Marinus Pharmaceuticals Inc Stock (MRNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):